Product Description
for Treatment of Incisional Wounds Following Breast Reconstruction Surgery (Sourced from: https://clinicaltrials.gov/ct2/history/NCT01053897?V_3=View)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Garnet BioTherapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Injuries/wounds Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01053897 |
GBT-09-001 | P2 |
Completed |
Injuries/wounds Unspecified |
2011-10-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|